Provided by Tiger Fintech (Singapore) Pte. Ltd.

Incyte

68.25
-1.7300-2.47%
Volume:1.52M
Turnover:104.30M
Market Cap:13.21B
PE:703.43
High:70.15
Open:70.00
Low:68.21
Close:69.98
Loading ...

Incyte Corp. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Yesterday

Incyte Is Maintained at Neutral by JP Morgan

Dow Jones
·
Yesterday

J.P. Morgan Reaffirms Their Hold Rating on Incyte (INCY)

TIPRANKS
·
14 Jul

Insider Moves: Constellation, Pure, Appian, Box, Incyte

TIPRANKS
·
12 Jul

Incyte Corp. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
12 Jul

Incyte’s Phase 1 Study Completion: A Boost for Oncology Innovations

TIPRANKS
·
12 Jul

Incyte’s Phase 3 Study on Ruxolitinib Cream for Hidradenitis Suppurativa: A Potential Game-Changer

TIPRANKS
·
12 Jul

Press Release: Incyte to Report Second Quarter Financial Results

Dow Jones
·
10 Jul

Incyte Corporation to Announce Second Quarter Financial Results

Reuters
·
10 Jul

Incyte Corp. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
10 Jul

Don't Ignore The Insider Selling In Incyte

Simply Wall St.
·
09 Jul

Incyte Executives Cash In: Major Stock Sales Revealed!

TIPRANKS
·
08 Jul

Incyte Corp. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
08 Jul

Barry P. Flannelly, EVP & General Manager US, Reports Disposal of Incyte Corporation Common Shares

Reuters
·
08 Jul

Sheila A. Denton, EVP & General Counsel, Reports Disposal of Incyte Corporation Common Shares

Reuters
·
08 Jul

Vijay K. Iyengar, EVP of GMAPPS, Reports Disposal of Common Shares in Incyte Corporation

Reuters
·
08 Jul

RBC Capital Sticks to Their Hold Rating for Incyte (INCY)

TIPRANKS
·
08 Jul

RBC Raises Price Target on Incyte to $68 From $67, Keeps Sector Perform Rating

MT Newswires Live
·
07 Jul

Incyte’s Ruxolitinib Cream Study: A Closer Look at Maternal and Infant Outcomes

TIPRANKS
·
04 Jul

Incyte’s Phase 3 Study Update: Potential Market Impact for HNSCC Treatment

TIPRANKS
·
04 Jul